Adjuvant Chemotherapy

In this video, Lionel Aurelien Kankeu Fonkoua, MD, discusses areas of research that need to be explored in treating cholangiocarcinoma.

A shortened adjuvant chemotherapy regimen improved outcomes for infants with unilateral pathologic high-risk retinoblastoma, according to study results.

The addition of pembrolizumab to adjuvant chemotherapy improved DFS for certain women with newly diagnosed high-risk endometrial cancer, according to randomized phase 3 study results presented at ESMO Congress.

Modified FOLFIRINOX induction chemotherapy prior to standard chemoradiation, surgery and adjuvant chemotherapy improved outcomes for patients with locally advanced rectal cancer, according to a long-term analysis of a randomized phase 3 trial.

Updated findings from a randomized trial yielded new insights into the optimal duration of adjuvant trastuzumab for women with HER2-positive breast cancer.

Cognition appeared associated with likelihood that individuals would return to work 2 years after breast cancer diagnosis, according to results of a case series study.

Timing of adjuvant chemotherapy initiation may affect outcomes among patients who undergo surgery for colorectal cancer, according to data published in JAMA Surgery.

Adjuvant durvalumab failed to improve outcomes compared with placebo for certain patients with early-stage lung cancer, according to the agent’s manufacturer.

A clinical trial at Keck Medicine of USC will investigate a new surgical approach to treating patients with locally advanced pancreatic cancer.

A personalized cancer vaccine produced T-cell responses in certain patients with head and neck squamous cell carcinoma, according to results from a randomized study presented at American Association for Cancer Research Annual Meeting.